With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
CL — frequently asked questions
Is Colgate-Palmolive Company overvalued?
In our latest published analysis dated 2026-09-27, CL screens modestly overvalued. The price recorded at analysis is USD 86.1 versus our fair value of USD 74.0; the high endpoint is presented separately as potential value of USD 102. That implies roughly 14.0% downside to fair value at that date.
Our latest published report, analyzed 2026-09-27, gives CL a fair value of USD 74.0 and a potential value of USD 102. The conclusion is triangulated across multiple valuation models and weighted by reliability for Colgate-Palmolive Company's archetype; it is a dated research output, not a live price.
Should I buy CL now?
Our latest published rating for CL, analyzed 2026-09-27, is Reduce. Colgate-Palmolive Company screens modestly overvalued at the analysis-date price of USD 86.1 versus fair value of USD 74.0; potential value is USD 102. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for CL?
The dedicated bear-case section in our report analyzed 2026-09-27 documents Colgate-Palmolive Company's material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is CL's rating?
Our latest published rating for CL, analyzed 2026-09-27, is Reduce, with a published moat assessment of 9/10 (Wide). It reflects our fair value of USD 74.0, the potential value of USD 102, and the price recorded at analysis (USD 86.1).
Accelerating global adoption and veterinarian recommendations for Hill's Pet Nutrition ($4.61B revenue in FY2025), combined with premium oral care tiering across emerging markets in Latin America and Asia, drives sustained 4-5% organic revenue growth, lifts gross margins beyond 62.0%, and normalizes operating margins above 20.5% toward our Potential value of $101.51.
Main risk
North American shipment volumes trail consumption by more than 2 percentage points for two consecutive quarters, coupled with Walmart revenue share falling below 9.0%,.
We assign a Reduce rating to Colgate-Palmolive Company, as the stock price of $86.06 on September 25, 2026 sits 16.3% above our fundamental Fair value of $74.00,.3
Our Reduce rating indicates that investors should trim holdings or avoid allocating fresh capital to Colgate-Palmolive at current valuation levels. While the company is an exceptional defensive business with dependable dividend distributions, the market price has outrun fundamental cash-generation power. Investors face an unfavorable risk-reward profile where prospective returns fail to compensate for slowing category volume growth and margin headwinds.4
On September 25, 2026, the stock closed at $86.06. This price trades at a 16.3% premium to our Fair value midpoint of $74.00, representing 14.01% downside. Our valuation range indicates a Potential value of $101.51 under favorable long-term execution. However, achieving Potential value requires sustained gross margin expansion beyond 62% and accelerated volume growth in emerging markets,. At $86.06, the shares already price in aggressive operational recovery and leave little margin of safety.3,4
The primary risk that would accelerate downside is permanent working capital reduction by key mass retailers like Walmart, which represents 11.0% of net sales. In the second quarter of 2026, North American shipments fell 3% even as consumption grew 1%, because retail partners actively managed to leaner inventory baselines,. If retailers permanently cut inventory and expand private-label shelf space, shipment volumes will lag consumer demand, forcing Colgate to maintain double-digit increases in advertising spend to defend market share,. That cost pressure would cap operating margins near 17.5% and cause free cash flow to fall short of expectations.4,7,8
The primary driver that could support the stock toward our Potential value of $101.51 is continued science-backed premiumization in Hill's Pet Nutrition alongside international oral care expansion,. Hill's delivered $4.61 billion in revenue in 2025 and generates pricing power through veterinarian endorsements,. If premium pet food and specialized dental therapies accelerate consolidated organic sales growth to 4-5% while raw material costs remain benign, gross margins can sustain above 61.5%,. Operating leverage would then lift operating margins above 20.5% and push earnings per share toward $4.75 by 2030, raising intrinsic value per share.4,
Global Oral Care Market Leadership
Colgate holds an entrenched global market position in toothpaste and manual toothbrushes, generating $15.77B in Oral, Personal and Home Care revenue in 2025.8
High-Margin Pet Nutrition Engine
Hill's Pet Nutrition generated $4.61B in 2025 sales and leverages veterinary endorsements to command premium pricing power and strong cash generation,.4,8
Dependable Dividend Aristocrat Cash Returns
Colgate maintains an unbroken multi-decade record of annual dividend increases supported by $3.63B in free cash flow and a modest 2.77% capex-to-revenue intensity,.
House recommendation
We rate Colgate-Palmolive Reduce because the stock trades at $86.06, a 16.3% premium to our Fair value of $74.00, reflecting unrealistic margin and volume expectations amidst retailer inventory compression,,.3,4
Company overview
COLGATE-PALMOLIVE COMPANY operates in two product segments: Oral, Personal and Home Care; and Pet Nutrition. COLGATE-PALMOLIVE COMPANY is a leader in Oral Care with global leadership in the toothpaste and manual toothbrush categories according to market share data.
Under an integrated stress scenario where normalized cycle cost of equity reaches 8.5562%, retailers permanently depress working capital holding baselines, and advertising reinvestment remains elevated in double digits, Colgate's valuation compresses toward the lower bound of $50.65. At the share price of $86.06, trading at a forward P/E of 20.96x, the stock carries a 16.30% premium over Fair value of $74.00, leaving minimal valuation cushion against structural retail pushback or macro cost shocks.
Colgate-Palmolive possesses a wide economic moat rooted in dominant global oral care market share, entrenched consumer mindshare, and unmatched professional dentist advocacy. The core Oral, Personal and Home Care segment delivered $15,769M in FY2025 revenue, representing 77.37% of consolidated net sales of $20,382M. This foundation is reinforced by Hill's Pet Nutrition ($4,613M in FY2025), which operates a prescription and therapeutic nutrition model driven by clinical veterinary endorsements. Together, these franchises generate consistent, inelastic consumer demand across economic cycles.
Colgate's competitive advantage is reflected in exceptional return metrics, posting a return on invested capital of 38.62% that substantially surpasses its computed moderate cost of equity of 7.20% and computed WACC of 6.90%. The company's pricing power is demonstrated by reaching 60.11% in FY2025 ($12,251M on $20,382M ) and expanding to 61.48% in Q2 2026 ($3,296M gross profit on $5,361M revenue,). These margins meaningfully exceed consumer defensive peers including Procter & Gamble (50.87%), Kenvue (58.44%), and Archer-Daniels-Midland (6.87%,), confirming structural profitability advantages.
The highlighted cell is Fair value when every assumption sits at its base level ($74.00). Each row and column shows what Fair value becomes when one assumption moves.
Upgrade the rating; Pause trimming actions; verify whether volume improvements in untracked channels and gross margin gains persist into subsequent quarters before considering re-allocating capital
An upside inflection where shipment volumes catch up to underlying consumption and untracked channel market share stabilizes would confirm that operating margin targets can be achieved ahead of schedule, reducing downside risk relative to $74.00
In-line
Maintain Reduce; Proceed with scheduled portfolio reduction toward an underweight allocation, rebalancing capital into alternatives with greater margin of safety
Trigger: Organic sales growth meets consensus projections with gross margins remaining stable and operating margins matching target recovery path
Household and personal products industry capex-to-revenue stands at 1.1% (0.011) and industry capex-to-depreciation stands at 1.07 as of September 2026. Colgate-Palmolive invested $564M in capex in FY2025 on $20,382M revenue (2.77% capex-to-revenue), while industry operating margin benchmark is 18.8% and gross margin is 51.0%.7
Bull cycle
In an industry upcycle, consumer spending in oral health and pet nutrition accelerates toward premiumized clinical formulations, emerging market household incomes expand per-capita toothpaste usage, and mass retailers expand shelf space and inventory allocations, allowing consumer defensive leaders to deliver 4-6% organic revenue growth and expand beyond 62%.
§11 Position management
Sizing
0-1%
Colgate-Palmolive trades at $86.06, representing a 16.30% premium over synthesized Fair value of $74.00 and implying an upside of -14.01%. At a forward P/E of 20.96x, the stock commands an unwarranted premium over peers such as Procter & Gamble at 19.76x and Kenvue at 14.36x,. Consequently, an underweight portfolio allocation of 0-1% is recommended, advising investors to trim holdings.2,3
Risk
Risk management focuses on capital preservation given negative expected returns (-14.01%). Investors should rebalance out of CL into defensive staples offering favorable risk-reward profiles. Portfolio exposure should be capped at 1% of total equity assets, using any price strength above $88.00 as an opportunity to complete orderly divestment.
§12 Investor perspectives
Value-Focused Investor
Avoid
Colgate trades at a forward P/E of 20.96x, commanding a rich premium over peer leader Procter & Gamble at 19.76x and Kenvue at 14.36x,. With the stock trading at an implied 16.3% premium to our Fair value of $74.00, value investors should avoid initiating positions until a meaningful margin of safety emerges.2,3
Dividend & Income Investor
Hold
Colgate is a premier Dividend Aristocrat with 61 consecutive years of dividend increases, backed by $3.63B in free cash flow and a healthy dividend payout. Existing income-focused shareholders can hold for steady distributions, but should avoid reinvesting dividends at current valuations above $86.3,
§14 Final recommendation
Action
Reduce
We recommend reducing exposure to Colgate-Palmolive Company. At $86.06 on September 25, 2026, the stock trades at a 16.3% premium over our Fair value of $74.00,. While Colgate is an exemplary consumer defensive business with an enviable 38.62% return on invested capital, current pricing already reflects an aggressive operational recovery, leaving zero margin of safety against retail inventory compression.1,3,4
Investors should capitalize on current trading multiples (20.96x forward P/E) to lock in gains and redeploy into consumer defensive peers offering wider margins of safety or higher cash yields. Maintain trailing stop-losses and monitor retail shipment recovery in upcoming quarters.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Mass retailers permanently manage to reduced inventory holding baselines
Private-label substitution accelerates in essential mass categories
Elevated advertising expenditures fail to prevent volume slippage in untracked channels
Cost of capital normalizes toward historical sector baseline levels
In the bear outcome, persistent retailer inventory minimization combines with private-label substitution to compress shipment volumes, while necessary advertising spending restrains operating margin recovery. A normalization in the cost of capital further contracts valuation multiples. This downside path would be confirmed by consecutive quarters of shipment declines relative to consumption and gross margin deterioration.
The valuation's moderate cost of equity of 7.20% relies on an unsustainably low raw beta of 0.3352. If the discount rate normalizes toward the cycle cost of equity of 8.5562% (+200 bps shock), DDM fair value falls by -30.1% and discounted earnings fair value contracts by -32.2%, driving a -30.5% valuation contraction.1
Colgate trades at a forward P/E of 20.96x while peer leader Procter & Gamble trades at 19.76x and Kenvue trades at 14.36x. With management cautioning that category demand is unlikely to inflect positively in H2 2026, multiple compression from 19.5x to peer median of 15.6x (-20%) reduces forward earnings fair value by -20.0%.2,3,4
FV impact
-1.5%
Terminal multiple 20% lower
Trigger
Structural Reinvestment and Input Cost Pressure Caps Operating Margins
FY2025 operating margin was 16.22% ($3,306M on $20,382M revenue,). If normalized operating margins stall at 17.5%—3.0 percentage points below the 20.5% normalized target—due to mandatory double-digit advertising spending to combat untracked channel share loss, and fading FX tailwinds, normalized earnings power contracts by -18.5%.4,7
FV impact
0%
Operating margin 3 points lower throughout
Trigger
Category Stagnation and Private-Label Substitution Halves Long-Term Growth
Mass retailers minimizing inventory baselines, Walmart expanding private label offerings (11.0% revenue share), and mature category volume stagnation reduce terminal growth by 100 bps from 2.5% to 1.5%, cutting DDM fair value by -14.8% and discounted earnings by -13.2%.4,8
FV impact
-10.1%
Terminal growth 1 point lower
Trigger
Within 36 months
Early-warning signals to monitor
The five developments that would weaken our investment case.
01
North American Shipment Growth Relative to Consumption
Persistent divergence indicates retailers are permanently compressing shelf inventory baselines or Colgate is losing channel market share,.
Current:Shipments down 3% versus consumption up 1% (Q2 2026)
Alert ifVolume shipments lagging measured retail consumption by more than two percentage points across two consecutive quarters
Confirms that required double-digit advertising reinvestment and input cost pressures are permanently capping margin recovery below the 20.5% normalized target,.
The durability of Colgate's moat is protected by extensive international distribution across more than 200 countries, limiting customer concentration risk. While Walmart Inc represents Colgate's largest retail customer at 11.0% of FY2025 net sales, 89% of revenue is broadly diversified across international supermarkets, independent grocers, pharmacies, and veterinary clinics. Sustained maintenance capital expenditures of $564M in FY2025 (2.77% of revenue) ensure modern supply chain infrastructure and localized manufacturing scale that cannot be easily replicated by regional competitors or private-label manufacturers.
Colgate's ROIC of 38.62% versus its computed WACC of 6.90% and moderate cost of equity of 7.20% yields an economic profit spread of 31.72 percentage points. This capital return profile reflects robust structural pricing power, as demonstrated by FY2025 consolidated gross margin of 60.11% ($12,251M gross profit on $20,382M revenue,) and Q2 2026 gross margin expansion to 61.48% ($3,296M gross profit on $5,361M revenue,). Even against a normalized cycle cost of equity of 8.5562%, Colgate maintains a 30.06 percentage point economic spread.1,5,7
9/ 10
Wide
Sources of advantage
01Global Distribution Network and Shelf Space Dominance — Colgate commands premier shelf space across global grocery, pharmacy, and mass merchant channels in over 200 countries, with single largest customer Walmart Inc accounting for 11.0% of FY2025 net sales and 89% distributed across independent and international channels.Wide
02Brand Equity and Professional Dentist Recommendation Intangibles — Colgate's flagship oral care franchise generated $15,769M in FY2025 revenue, supported by decades of dentist endorsements and consumer brand loyalty that enabled gross margins of 60.11% in FY2025 and 61.48% in Q2 2026, significantly exceeding peer gross margins (PG at 50.87%, KVUE at 58.44%, ADM at 6.87%,).Wide
03Proprietary Science-Based Formulations and Veterinary Network — Hill's Pet Nutrition generated $4,613M in FY2025 net sales leveraging a specialized veterinary recommendation model, clinical dietary formulations, and premium brand credentials.Moderate
Retailer Channel Margin Squeeze and Private-Label Substitution
medium
12-24 months
Continuous product premiumization, clinical efficacy tiering, and joint business planning with top retail partners like Walmart (11.0% of FY2025 revenue).8
Market Share Slippage in Untracked and E-Commerce Channels
medium
6-18 months
Management committed double-digit increases in advertising spend and targeted digital marketing innovation in disrupted markets like China to reverse untracked channel volume loss.4
Agricultural Commodity and Resin Packaging Cost Inflation
low
12-36 months
Proactive revenue growth management pricing actions, Funding the Growth productivity programs, and forward raw material contracting.4
In the base outcome, yielding $74.00 with an estimated probability of 60.0% and an expected return of -14.0%, Colgate-Palmolive delivers steady organic growth across its core franchises. Mass merchant channel inventory stabilizes, and gross profit gains are balanced by necessary advertising reinvestment to maintain defensive market share. However, because $86.06 trades above Fair value of $74.00, the expected return profile remains negative at -14.0%, validating a Reduce recommendation.
Terminal price-to-earnings valuation multiple expanding on premium brand positioning
In the bull outcome, projected at $101.51 with an estimated probability of 15.0% and an expected return of 18.0%, Colgate-Palmolive accelerates international oral care premiumization while Hill's Pet Nutrition expands veterinary market share globally. Gross margin gains outpace cost inflation, allowing operating margins to surpass historical peaks even after funding strong commercial marketing. This scenario would be disconfirmed if retail partners resist premium shelf allocation or if emerging market currency devaluations erode reported sales gains.
In-line performance confirms steady defensive cash conversion but leaves the valuation stretched, as $86.06 continues to trade at a substantial premium to $74.00
Miss
Downgrade the rating; Accelerate liquidation of remaining positions, setting checkpoints to monitor shelf-space losses and gross margin erosion across major retail accounts
Trigger: Organic sales contraction driven by retailer inventory minimization and private-label substitution, combined with operating margin compression from elevated commercial reinvestment
A failure in organic volume growth combined with gross margin erosion would disconfirm the pricing power thesis, indicating that retail customer pushback and advertising inflation are permanently impairing earnings power
CurrentShipments trailed consumption in the recent quarter due to retailer inventory reductions
Why it matters
When shipments diverge negatively from consumption, it reveals whether retailers are permanently managing to leaner inventory baselines or whether national brand shelf space is being ceded to private-label alternatives
02
Metric:
Gross Margin Durability Against Commodity Pressures
CurrentExpanded in recent quarters supported by pricing and temporary tariff benefits
Why it matters
Gross margin stability reveals whether pricing power remains intact as raw material costs evolve and retail partners push back on list prices
03
Metric:
Walmart Channel Concentration and Private Label Encroachment
CurrentSingle largest customer accounts for over one-tenth of total consolidated sales
Why it matters
Tracking customer concentration reveals whether mass retail partners are successfully expanding private-label penetration or extracting larger promotional allowances at the expense of national brand operating profit
04
Metric:
Commercial Advertising Reinvestment Ratio
CurrentAdvertising spend elevated at double-digit growth rates to protect untracked channel presence
Why it matters
Persistent double-digit advertising increases demonstrate whether promotional spending is defensive maintenance to stem share loss or productive demand generation that creates operating leverage
05
Metric:
Veterinary Pet Nutrition Volume Growth
CurrentMaintains steady revenue growth backed by clinical veterinary recommendations
Why it matters
Pet Nutrition provides the primary growth and premiumization driver outside oral care; deceleration here directly reduces consolidated top-line growth expectations
Colgate's cash generation exhibits high accounting fidelity and defensive consistency. FY2025 operating cash flow of $4,198M substantially exceeded GAAP net income of $2,132M,, delivering an operating cash conversion ratio of 1.97x net income. Free cash flow of $3,634M represented 17.83% of consolidated revenue ($20,382M). In Q2 2026, free cash flow grew 18%, driven by gross margin expansion to 61.48% ($3,296M gross profit on $5,361M revenue,). Modest annual capex requirements ($564M in FY2025, with maintenance capex estimated at 85% or $479.4M) ensure that over 85% of operating cash flow converts directly into discretionary owner earnings ($2,282.6M in normalized owner earnings).4,5,7
Colgate executes a disciplined, shareholder-friendly capital allocation strategy characteristic of a premier dividend aristocrat. In FY2025, the company generated $4,198M in operating cash flow and allocated just $564M to capital expenditures (2.77% of revenue), producing $3,634M in free cash flow. In Q2 2026, free cash flow expanded 18% year-over-year, enabling the return of $1.4B to shareholders via dividends and share repurchases. Total debt stands at $7,856,999,936 against a market capitalization of $68,604,690,000,, representing a manageable debt weight of 10.28% and pre-tax cost of debt of 5.72%.
Colgate's ROIC trajectory reflects enduring brand pricing power and an asset-light manufacturing model. While treasury share repurchases reduce stated book equity, underlying operational capital returns remain structurally insulated from cyclical compression.
Colgate's latest ROIC of 38.62% vastly outstrips its computed WACC of 6.90% and moderate cost of equity of 7.20%, generating a spread of over 31 percentage points.
FY2025 operating cash flow of $4,198M and capex of $564M delivered $3,634M in FCF, supporting $1.4B returned to shareholders in Q2 2026 alone.
Dividend safety and capital return durability remain uncompromised even during periods of volume stagnation.
Gross Margin Expansion Offset by Commercial Reinvestment
Q2 2026 gross margin reached 61.48% ($3,296M gross profit on $5,361M revenue; cost of revenue $2,065M), but operating income compressed in FY2025 to $3,306M (16.22% margin) as advertising spend stepped up by double digits.
Operating leverage is restrained as gross profit gains must be reinvested in advertising to defend untracked channel market share.
Valuation Disconnect Between Cash Return Models and Market Multiple
Current share price of $86.06 trades at forward P/E of 20.96x,, commanding a 16.30% premium over Fair value of $74.00 and well above cash return models like DDM ($51.65) and owner earnings ($55.84).
The market prices in full operating margin normalization toward 20.5% without discounting retail inventory and cost of capital risks.
Colgate-Palmolive Company (CL) trades at 21.0x forward earnings against a peer median of 17.1x. Its EV/EBITDA of 15.1x compares with a peer median of 15.3x. The comparison uses 4 peers: The Procter & Gamble Company, Archer-Daniels-Midland Company, Kenvue Inc. and The Estee Lauder Companies Inc., as of 2026-09-27.
In an industry downcycle, consumer spending power weakens, prompting down-trading to private-label alternatives at mass retailers like Walmart (11.0% customer revenue share), while mass retailers aggressively destock inventories to minimize working capital. Pricing power dissipates after upfront inflation realization, and intense promotional discounting across peers compresses operating margins below historical averages.
Secular trends
Trend
Impact
Note
Veterinary-Backed Premium Pet Nutrition Demand
positive
Pet humanization and increasing clinical veterinary care drive sustained demand for Hill's Pet Nutrition science-backed formulations, enabling volume and pricing growth above standard consumer staple rates.
Emerging Market Oral Hygiene Adoption and Premiumization
positive
Rising disposable incomes in Latin America, Asia Pacific, and Africa expand per-capita toothpaste and toothbrush consumption, while driving mix shift into higher-margin therapeutic oral care segments.
Retail Channel Inventory Minimization and Private-Label Expansion
negative
Mass retailers continuously deploy automated inventory systems to lower stock baselines while aggressively expanding store-brand oral care lines at retail partners like Walmart (11.0% revenue share), capping national brand volume growth.
Positioning
Colgate holds an advantaged position within consumer defensive staples due to its 77.37% concentration in essential Oral, Personal and Home Care ($15,769M in FY2025) and high-margin Pet Nutrition franchise ($4,613M in FY2025). Its gross margin of 60.11% in FY2025 and 61.48% in Q2 2026 outpaces peer Procter & Gamble at 50.87% and Kenvue at 58.44%, providing a superior gross profit buffer against cyclical downturns.7,8
Entry tranches
Level
Action
Why
$74.00 (Synthesized Fair Value Midpoint)
Consider initial nibble or neutral rebalancing only upon complete valuation reset
Realigns share price with fundamental fair value, eliminating the current 16.30% market valuation premium.
With upside capped and negative prospective returns of -14.01% to Fair value, tactical capital faces adverse asymmetry. Persistent retail destocking and subdued category growth in North America limit near-term catalysts for multiple expansion,.4
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
